OCIAD2 Antibody | 5463

OCIAD2 Antibody | 5463 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: Predicted species reactivity based on immunogen sequence: Mouse: (71%) , Bovine: (72%)

Immunogen: OCIAD2 antibody was raised against an 18 amino acid synthetic peptide from near the carboxy terminus of human OCIAD2.
The immunogen is located within the last 50 amino acids of OCIAD2.

Research Area: Cancer

Tested Application: E, WB, IF

Application: OCIAD2 antibody can be used for detection of OCIAD2 by Western blot at 0.5 - 1 μg/mL. Antibody can also be used for immunoflourescence starting at 5 μg/mL. For immunofluorescence start at 5 μg/mL.
Antibody validated: Western Blot in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1203 - A549 Cell Lysate

Positive Control 2: Cat. No. 17-003 - A549 Cell Slide

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: OCIAD2 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: OCIAD2 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: OCIAD2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: OCIAD2 Antibody: OCIA domain-containing protein 2, Ovarian carcinoma immunoreactive antigen-like protein

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: OCIAD2 Antibody: OCIAD2 was identified by its sequence similarity with OCIAD1, and together OCIAD1 and OCIAD2 form the OCIA domain family. OCIAD2 mRNA was found to be expressed at higher levels in invasive adenocarcinoma mixed subtype with bronchioloalveolar carcinoma component (BAC) of the lung. Loss of OCIAD2 expression was significantly correlated with lymphatic invasion, blood vessel invasion, and lymph node metastasis, indicating that OCIAD2 may play a role in cell adhesion and prevention of cell migration. While the function of OCIAD2 is still unknown, its expression in adenocarcinoma with BAC component is significantly associated with a favorable prognosis and may serve as a marker for selecting tumors that are treatable by limited surgery.